US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy’s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy’s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.
Financial Terms of the Agreement
Under the terms of the agreement, Sanofi will pay Alloy an aggregate of USD 27.5 million in upfront license fees and near-term preclinical milestone payments. Additionally, Alloy will be eligible to receive discovery, development, and commercial milestone payments exceeding USD 400 million, along with tiered royalties on product sales.
Significance of the Collaboration
This collaboration highlights the potential of Alloy Therapeutics’ AntiClastic Antisense Platform in developing innovative treatments for central nervous system disorders. By partnering with Sanofi, a global leader in pharmaceuticals, Alloy aims to accelerate the development and commercialization of novel CNS therapies, potentially improving patient outcomes and addressing significant unmet medical needs.-Fineline Info & Tech
